

**Brand Favored Product List
Health First Colorado Pharmacy Benefit**



Multi-source drug products with favored coverage for a brand name equivalent formulation are listed in this document. Drug products listed in this document include products not managed on the Preferred Drug List (PDL), as well as preferred and non-preferred products included on the PDL (accessible at <https://www.colorado.gov/hcpf/pharmacy-resources#PDL>).

Determination for products included on the Brand Favored Product List is based on the evaluation of cases where the cost of a generic product formulation exceeds the cost of the brand name equivalent.

Billing Information:

Pharmacy claims for brand medications/dosage forms included on the Brand Favored Product List will allow for payment with submission of DAW codes 1 or 9 on the incoming claim. PDL products included in the list may also be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

Prior Authorization for Use of a Generic Equivalent(s) Included on the Brand Favored Product List:

Generic equivalent products for the brand medications/dosage forms included on the Brand Favored Product List will require prior authorization and may receive approval based on prescriber verification that there is clinical necessity for the use of the generic equivalent product formulation.

Prior authorization requests may be called or faxed to the Magellan pharmacy helpdesk at:

Phone: 1-800-424-5725
Fax: 1-888-424-5881

The following products were added/removed:

- Alphagan P 0.1% (brimonidine) drop - added.

PDL PREFERRED BRAND FAVORED PRODUCTS*	
Drug Product	Effective Date
Adderall XR (mixed amphetamine salts ER) capsule	9/1/2020
Advair Diskus (fluticasone/salmeterol)	11/1/2019
Advair HFA (fluticasone/salmeterol)	3/1/2023
Alphagan P 0.15% (brimonidine) drop	4/1/2020
Alphagan P 0.1% (brimonidine) drop	9/4/2023
Amitiza (lubiprostone) capsule	1/1/2021
Apriso (mesalamine ER) capsule	11/26/2019
Azopt (brinzolamide) 1% drop	4/1/2022
Butrans (buprenorphine) transdermal patch	7/1/2019
Climara (estradiol) patch	10/1/2021
Combigan (brimonidine tartrate/timolol maleate 0.2%/0.5%) drop	1/27/2022

*Products may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL and Appendix P.

PDL PREFERRED BRAND FAVORED PRODUCTS* (continued)	
Drug Product	Effective Date
Concerta (methylphenidate ER) tablet	10/1/2017
Copaxone (glatiramer) 20 mg injection	4/1/2017
Copaxone (glatiramer) 40mg injection	4/1/2023
Coreg CR (carvedilol ER) capsule	7/1/2023
Daytrana (methylphenidate) patch	4/1/2023
Delestrogen (estradiol valerate) vial	10/1/2021
Derma-Smoothe-FS (fluocinolone acetonide) oil	4/1/2019
Dexilant (dexlansoprazole) capsule	7/1/2023
Diclegis DR (doxylamine/pyridoxine) tablet	1/1/2022
Denavir (penciclovir) cream	11/14/2022.
Elidel (pimecrolimus) cream	6/15/2021
Epipen 0.3 mg/0.3 ml (epinephrine) auto-injector	1/1/2022
Epipen JR 0.15 mg/0.15 ml, (epinephrine) auto-injector	1/1/2022
Felbatol (felbamate) tablet, suspension	10/1/2018
Finacea (azelaic acid) gel	7/1/2021
Flovent HFA (fluticasone) inhaler	5/23/2022
Humalog (insulin lispro) 100 U/mL vial	4/27/2023
Humalog (insulin lispro) 100 U/mL pen	4/27/2023
Humalog Jr. (insulin lispro) KwikPen	4/27/2023
Humalog Mix 75/25 (insulin lispro protamine/insulin lispro) KwikPen	4/27/2023
Imitrex (sumatriptan) nasal spray	1/1/2021
Imitrex (sumatriptan) cartridge, pen injector	4/1/2023
Lamictal (lamotrigine) dose pack	4/1/2023
Lialda (mesalamine DR) tablet	1/1/2019
Lotemax (loteprednol) 0.5% drop	7/2/2019
Migranal (dihydroergotamine) nasal spray	4/1/2023
Minivelle (estradiol) patch	10/1/2021
Nexium (esomeprazole) packet	2/25/2017
Nuvaring (etonorgestrel/ethinyl estradiol) vaginal ring	10/1/2021
Pentasa (mesalamine) ER capsule	5/17/2022
Pradaxa (dabigatran) capsule	6/27/2022
Proair (albuterol) HFA inhaler	2/18/2019
Protonix (pantoprazole) packet for oral suspension	7/1/2023
Proventil (albuterol) HFA inhaler	10/1/2022
Pylera (bismuth subcitrate/metronidazole/tetracycline) capsule	3/6/2023
Renvela (sevelamer carbonate) powder pack	7/1/2021
Renvela (sevelamer carbonate) tablet	7/1/2021
Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vial	2/4/2022
Retin-A (tretinoin) cream, gel	7/1/2021
Saphris (asenapine) SL tablet	4/1/2023
Spiriva Handihaler (tiotropium)	8/15/2023
Symbicort (budesonide/formoterol) inhaler	1/16/2018
Taclonex (calcipotriene/betamethasone) ointment	1/1/2019
Taclonex Scalp (calcipotriene/betamethasone) suspension	1/1/2019
Toviaz (fesoterodine ER) tablet	6/27/2022
Travatan Z (travoprost) drop	1/1/2020
Ventolin (albuterol) HFA inhaler	4/10/2020
Vivelle-Dot (estradiol) patch	10/1/2021
Vyvanse (lisdexamfetamine) capsule	8/25/2023
Zomig (zolmitriptan) nasal spray	8/10/2023

*Products may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL and Appendix P.

PDL NON-PREFERRED BRAND FAVORED PRODUCTS*	
Drug Product	Effective Date
Apokyn (apomorphine) cartridge	5/12/2022
Banzel (rufinamide) suspension	4/22/2021
Banzel (rufinamide) tablet	11/11/2021
Duexis (ibuprofen-famotidine) tablet	8/13/2021
Dymista (azelastine/fluticasone) spray	4/1/2019
Flector (diclofenac) topical system	5/14/2020
Hetlioz (tasimelteon) capsule	1/10/2023
Sabril (vigabatrin) tablet/solution	7/16/2019
Trokendi XR (topiramate ER) capsule	4/27/2023
Vimovo (naproxen/esomeprazole) DR tablet	2/26/2020

NON-PDL BRAND FAVORED PRODUCTS*	
Drug Product	Effective Date
Afinitor (everolimus) disperz tablet	1/1/2022
Buphenyl (sodium phenylbutyrate) tablet	10/15/2020
Ciprodex (ciprofloxacin/dexamethasone) suspension	1/20/2020
Moviprep (PEG 3350-electrolytes) powder for reconstitution	4/27/2023
Noxafil (posaconazole) tablet	5/28/2019
Rapamune (sirolimus) solution	10/15/2020
Rapamune (sirolimus) tablet	3/21/2022
Revlimid (lenalidomide) capsule	8/1/2019
Suprep (sodium-potassium-mag sulfates solution)	11/17/2022
Sutent (sunitinib) capsule	7/21/2022
Zavesca (miglustat) capsule	5/12/2022

*Products may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL and Appendix P.